Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

This study has been completed.
National Cancer Institute (NCI)
Bristol-Myers Squibb
Information provided by (Responsible Party):
Gynecologic Oncology Group Identifier:
First received: July 8, 2004
Last updated: February 12, 2014
Last verified: February 2014